AC Immune SA announced the pricing of its upsized initial public offering of 6,000,000 of its common shares at the initial public offering price of $11.00 per common share at NASDAQ. AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials.   After deducting the underwriting discounts and other estimated offering expenses, the net proceeds of the initial public offering are expected to be approximately $57.8 Mio. AC Immune’s common shares have been approved for listing on the NASDAQ and are expected to begin trading under the ticker symbol "ACIU" on September 23, 2016.

Credit Suisse Securities (USA) LLC, Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. VISCHER AG and Davis Polk & Wardwell London LLP are legal advisors to the Company. VISCHER AG has been advising AC Immune since inception in 2003. The team at VISCHER is led by Matthias Staehelin (Partner Corporate) with Stefan Grieder (Partner Corporate), Nadia Tarolli (Partner Tax), Christian Wyss (Partner Corporate), Vincent Reardon, Angelo Imperiale and Eric Flückiger (all Associates).